spacer
home > ebr > winter 2002 > crossbreeding and commercial consolidation in the uppsala biotech cluster
PUBLICATIONS
European Biopharmaceutical Review

Crossbreeding and Commercial Consolidation in the Uppsala Biotech Cluster

The Uppsala region has undergone a remarkable transformation in the biomedical area since the mid-1990s. The city, which lies about 70 kilometres north of the Swedish capital Stockholm, has seen a virtual explosion of research projects, business initiatives, entrepreneurial activity, new companies and industrial investment in the biotechnology and life science sectors.

Tradition, cutting edge research, access to human and financial capital, as well as a growing global market demanding solutions relying on biotech research and development, has created what has become known as the 'Uppsala Phenomenon'. "Today there are about 140 life science companies in Uppsala, of which more than 50 are biotech companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Per Odebrant, Freelance Science and Business Journalist
Per Odebrant is a Swedish freelance journalist specialising in science and business issues. He has a particular focus on applications of biotechnology, information technology and materials science. He also writes on matters concerning management, industrial organisation and intellectual capital. Per contributes to various national dailies, national and international magazines, and trade journals. He has also been a Consultant Project Manager to the Swedish Government's Information Technology Commission.
Per holds a degree in Philosophy/Linguistics from the University of Lund and has authored three novels. He was commissioned to write this article by STUNS, the Foundation for Collaboration between the Universities in Uppsala, the Business Community and Society.

spacer
Per Odebrant
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement